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Abstract
Objective: To investigate the association between serum 25-hydroxyvitamin D [25(OH)D] level and history of
community-acquired pneumonia (CAP).
Patients and Methods: We identified 16,975 individuals (≥17 years) from the third National Health and Nutrition
Examination Survey (NHANES III) with documented 25(OH)D levels. To investigate the association of 25(OH)D with
history of CAP in these participants, we developed a multivariable logistic regression model, adjusting for
demographic factors (age, sex, race, poverty-to-income ratio, and geographic location), clinical data (body mass
index, smoking status, asthma, chronic obstructive pulmonary disease, congestive heart failure, diabetes mellitus,
stroke, chronic kidney disease, neutropenia, and alcohol consumption), and season. Locally weighted scatterplot
smoothing (LOWESS) was used to depict the relationship between increasing 25(OH)D levels and the cumulative
frequency of CAP in the study cohort.
Results: The median [interquartile range (IQR)] serum 25(OH)D level was 24 (IQR 18–32) ng/mL. 2.1% [95%
confidence interval (CI): 1.9–2.3] of participants reported experiencing a CAP within one year of their participation in
the national survey. After adjusting for demographic factors, clinical data, and season, 25(OH)D levels <30 ng/mL
were associated with 56% higher odds of CAP [odds ratio 1.56; 95% confidence interval: 1.17–2.07] compared to
levels ≥30 ng/mL. LOWESS analysis revealed a near linear relationship between vitamin D status and the cumulative
frequency of CAP up to 25(OH)D levels around 30 ng/mL.
Conclusion: Among 16,975 participants in NHANES III, 25(OH)D levels were inversely associated with history of
CAP. Randomized controlled trials are warranted to determine the effect of optimizing vitamin D status on the risk of
CAP.
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Introduction
Community-acquired pneumonia (CAP) is a common and
potentially serious illness, which is associated with
considerable morbidity and mortality [1]. Indeed, CAP is the
leading infectious cause of death worldwide [2]. In the United
States, it is estimated that there are over 4 million ambulatory
care visits for CAP every year [3], resulting in excess of 1
million hospitalizations [4]. While the commercial availability of
penicillin in the 1950s significantly improved survival in patients
with pneumonia, advances in antimicrobial therapy since then
have not resulted in further attenuation of mortality attributable
to CAP [5]. Roughly 50,000 adults die from CAP each year in
the United States [6]. Hospital and intensive care unit (ICU)
admission rates continue to increase [7], and the annual direct
and indirect cost associated with the care of patients with CAP
exceeds $17 billion [5].
CAP is defined as an infection of the lung parenchyma that is
not acquired in a healthcare setting [4]. Although it is thought to
be primarily a result of pathogenic bacteria from the upper
respiratory system or aspiration of material from the
gastrointestinal tract, the exact pathophysiology is poorly
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understood [1,8]. Indeed, only a fraction of individuals in the
general population with upper respiratory infections (URI) or
those who aspirate progress to a fulminant pulmonary infection.
In recent years, considerable interest has focused on
circumstances that influence susceptibility to CAP, which has
lead to the appreciation of independent risk factors such as
smoking, asthma, and chronic obstructive pulmonary disease
(COPD) [1,7]. Recently, in small or moderately sized cohorts of
elderly, community-dwelling individuals, serum 25-
hydroxyvitamin D [25(OH)D] levels were shown to be
associated with the risk of CAP [9-11]. Given its central role in
immune regulation, and its known association with various
respiratory ailments (e.g. URI, asthma, COPD, tuberculosis)
[12-14], vitamin D status may also be associated with CAP in
the general adult population. Therefore, our goal was to
investigate the association of 25(OH)D levels with history of
CAP in a large, nationally-representative cohort of non-
institutionalized individuals from the United States.
Methods
The Third National Health and Nutrition Examination Survey
(NHANES III) has been used extensively to report on the
association of various biomarkers with major diseases.
Conducted by the National Center for Health Statistics between
October 18, 1988, and October 15, 1994, this cohort is
regarded as a nationally-representative, cross-sectional sample
of the non-institutionalized civilian population of the United
States. We conducted a secondary analysis of this dataset.
The Partners Human Research Committee granted an
“exempt” status for the study.
Data collection
Detailed survey methods, including sampling, interview,
examination, laboratory measurements, ethics approval, and
informed consent have previously been reported. In summary,
the survey used a complex, stratified, multistage probability
sample design. The NHANES III collected demographic
information, biometric measurements, as well as data on health
and nutrition on approximately 40,000 adults and children. The
surveys were performed during scheduled in-home interviews,
while physical examinations and laboratory testing were
performed in either a mobile examination center or during a
home visit. Blood samples collected during the examination
were centrifuged, aliquoted, and stored at −70°C on-site. They
were then shipped on dry ice to central laboratories, where
they continued to be stored at −70°C until analysis. 25(OH)D
levels were measured using a radioimmunoassay kit after
extraction with acetonitrile (DiaSorin, Stillwater, MN) by the
National Center for Environmental Health (Atlanta, GA).
Data abstraction
We identified 20,039 individuals, 17 years and older, in the
NHANES III dataset. From the household interview data file,
we reported information on all participants related to self-
reported: 1) age; 2) sex; 3) race; 4) poverty-to-income ratio
(measure of socioeconomic status); and 5) geographical
location. We also recorded current smoking status and self-
reported current: 1) asthma; 2) chronic obstructive pulmonary
disease (COPD); and 3) alcohol consumption. Additionally, we
recorded self-reported history of congestive heart failure (CHF),
diabetes mellitus (DM), and stroke. A diagnosis of COPD was
based on responses to questions on emphysema and/or
chronic bronchitis. From the physical examination data, we
calculated body mass index (BMI). Furthermore, we used the
laboratory data to document cases of neutropenia and to
calculate estimated glomerular filtration rates (eGFRs) to
assess for chronic kidney disease (CKD). To most accurately
adjust for the effect of season on 25(OH)D levels, the date of
the laboratory data collection was recorded. We limited our
analysis to the 16,975 participants with reported 25(OH)D
levels (primary exposure). The primary outcome (history of
CAP) was based on the response to the following question:
“During the past 12 months, have you had pneumonia?”
Statistical analysis
All statistical analyses were performed using Stata 12.0
(StataCorp LP, College Station, Texas). Using survey
commands, we applied the recommended subsample weights
for the interview plus examination data to account for unequal
probabilities of selection and to accurately represent estimates
for the population of the United States. All of the results are
presented as weighted values. We calculated variance based
on NHANES-provided masked variance units using the Taylor
series linearization method. All reported P values are 2-tailed,
with P<0.05 considered statistically significant. We calculated
proportions with 95% confidence intervals (CIs) for
demographic features and other factors thought to be related to
CAP, overall and in the subset of participants with self-reported
history of CAP within 12 months of the interview.
For our primary analysis, we categorized serum 25(OH)D
levels a priori as <30 ng/mL vs. ≥30 ng/mL. Based on existing
guidelines [15], We sub-categorized 25(OH)D levels <30 ng/mL
as <10 ng/mL, 10 to 19.9 ng/mL, and 20 to 29.9 ng/mL. To
improve interpretability of the analysis, we converted age, BMI,
geographic location, and season of blood draw into commonly
used groupings. Specifically, we categorized geographic
location into Northeast, Midwest, South, and West regions.
Season of blood draw was categorized into Winter (December-
February), Spring (March-May), Summer (June-August), and
Fall (September-November). In addition, we dichotomized: 1)
sex (female versus male); 2) race (non-white versus white); 3)
poverty-to-income ratio (≤ federal poverty level versus federal
poverty level); 4) smoking status; 5) CKD (eGFR <60 versus
≥60); 6) neutropenia (white blood cell count <3.5x103 versus
≥3.5 x103); and 7) alcohol consumption (≤30 versus >30 drinks
per month). We also dichotomized self-reported histories of: 1)
asthma; 2) COPD; 3) CHF; 4) DM; and 5) stroke. We
determined unadjusted associations between risk factors and
the outcome of CAP using the Pearson χ2 test for categorical
variables and simple ordinal logistic regression for ordinal
variables. To evaluate the independent association between
serum 25(OH)D level and history of CAP, we created
multivariable models by progressively adding covariates that
might confound or alter the association of 25(OH)D with history
Vitamin D and Community-Acquired Pneumonia
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of CAP. All adjusted odds ratios (ORs) for the variables in the
models are reported with 95% confidence intervals (CIs).
Locally weighted scatter plot smoothing (LOWESS) was
used to graphically represent the association between
25(OH)D level and the cumulative frequency of CAP. LOWESS
is a type of nonparametric regression, which summarizes the
relationship between two variables in a fashion that initially
relies on limited assumptions about the form or strength of the
relationship [16]. The rationale and methods underlying the use
of LOWESS for depicting the local relationship between
measurements of interest across parts of their ranges are
available elsewhere [17].
Results
Characteristics of the weighted NHANES III sample are
given in Table 1. The median age of the participants was 43
(IRQ 29-64) years; 53% were female and 68% were white.
Overall, the median serum 25(OH)D level was 24 (IRQ 18-32)
ng/mL. 2.1% (95%CI 1.9-2.3) of the overall cohort reported an
episode of CAP within twelve months of their NHANES III
interview. The proportions of participants with CAP, stratified by
individual characteristics, are also given in Table 1.
Compared with individuals with 25(OH)D levels ≥30 ng/mL,
those with levels <30 ng/mL had a 56% higher adjusted odds of
CAP (OR 1.56; 95%CI 1.17-2.07) within one year of the
interview. Looking within the large group of participants with
25(OH)D levels <30 ng/ml, we found higher adjusted odds of
CAP for those with levels <10 ng/mL (OR 2.25; 95%CI
1.26-4.01), 10-19.9 ng/mL (OR 1.26; 95%CI 0.89-1.79), and
20-29.9 ng/mL (OR 1.70; 95%CI 1.26-2.29). Other
characteristics associated with CAP included age, race,
asthma, COPD, CHF, and DM (Table 2).
Although the subcategories of 25(OH)D suggested a rough
dose-response association, LOWESS analysis showed a near
linear relationship between 25(OH)D level and the cumulative
frequency of CAP up to 25(OH)D levels around 30 ng/mL
(Figure 1). Between 25(OH)D levels of 30 ng/mL and 60 ng/mL
there was a progressive flattening of the curve.
Discussion
In this large nationally-representative study, we investigated
whether 25(OH)D level was associated with history of CAP
among adults in the United States. We demonstrated that
25(OH)D levels <30 ng/mL were indeed associated with a
significant increase in the odds of CAP in the general
population. While others have also hypothesized that vitamin D
status may play an important protective role against various
pulmonary diseases, our work provides important evidence to
suggest that vitamin D supplementation may offer a novel
approach to lowering the risk of CAP. Given the observational
nature, and cross-sectional design of our current study, a
causal inference about the effect of low vitamin D status and
higher risk of CAP is not possible; however, the biological
plausibility is undeniable.
Recently, cells of the innate and adaptive immune system
have been shown to express the vitamin D receptor [18].
Table 1. Characteristics of the overall study cohort and in





CAP - Number of
Observations (% of
overall study subsets) P-value
25(OH)D    
<10 ng/mL 641 20 (3.12) <0.001
10-19.9 ng/mL 5110 85 (1.67)  
20-29.9 ng/mL 5931 144 (2.43)  
≥30 ng/mL 5293 72 (1.36)  
Season    
Winter 4555 84 (1.84) 0.15
Spring 5415 127 (2.35)  
Summer 4456 98 (2.20)  
Fall 5613 102 (1.82)  
Age    
17-39 years 8602 101 (1.17) <0.001
40-60 years 4851 115 (2.37)  
≥60 years 6586 195 (1.77)  
Sex    
Female 10641 245 (2.30) 0.008
Male 9398 166 (1.77)  
Race    
Non-white 6310 87 (1.38) <0.001
White 13729 324 (2.36)  
Poverty ratio    
≤FPL 4295 86 (2.00) 0.86
>FPL 15744 324 (2.06)  
BMI    
<20 kg/m2 1470 49 (3.33) 0.004
20-24.9 kg/m2 7163 134 (1.87)  
25-29.9 kg/m2 6446 123 (1.91)  
≥30 kg/m2 3567 82 (2.30)  
Region    
Northeast 29298 50 (1.71) 0.31
Midwest 3852 86 (2.33)  
South 8556 169 (1.98)  
West 4703 106 (2.25)  
Smoking    
Yes 4990 110 (2.20) 0.39
No 15049 301 (2.00)  
Asthma    
>30 drinks per month 1376 94 (6.83) <0.001
>30 drinks per month 18663 317 (1.70)  
COPD    
Yes 1421 128 (9.00) <0.001
No 18618 279 (1.52)  
CHF    
Yes 757 56 (7.40) <0.001
No 19265 353 (1.83)  
Diabetes mellitus    
Yes 1614 70 (4.33) <0.001
No 18410 341 (1.85)  
Stroke    
Yes 649 23 (3.54) 0.006
No 19393 388 (2.00)  
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Vitamin D appears to be necessary for interferon-γ dependent
T cell responses to infection [19]. And, in low vitamin D states,
dysfunctional macrophage activity becomes evident [20].
Vitamin D is also an important link between Toll Like Receptor
(TLR) activation and antibacterial response [21]. Human
macrophages stimulated by TLR induce: 1) vitamin D receptor
expression [22]; 2) conversion of 25(OH)D to its most
biologically active form of 1,25-dihydroxyvitamin D [23]; and 3)
production of cathelicidin (LL-37), an endogenous antimicrobial
peptide with potent activity against bacteria, viruses, fungi, and
mycobacteria [24-26]. LL-37 is highly expressed at natural
barrier sites (e.g. skin, gut, lungs) and may represent an







CAP - Number of
Observations (% of
overall study subsets) P-value
CKD    
eGFR <60 3388 92 (2.72) <0.001
eGFR ≥60 12872 221 (1.72)  
Neutropenia    
WBC <3.5x103 187 2 (1.07) 0.393
WBC ≥3.5x103 16983 328 (1.93)  
Alcohol consumption    
≤30 drinks per month 1211 21 (1.73) 0.428
>30 drinks per month 18771 389 (2.07)  
CAP = Community-acquired pneumonia; 25(OH)D = 25-hydroxyvitamin D; FPL =
federal poverty level; BMI – body mass index; COPD = chronic obstructive
pulmonary disease; CHF = congestive heart failure; CKD = chronic kidney disease;
eGFR = estimated glomerular filtration rate; WBC = white blood cell count. P-
values are based on the chi-square test for categorical variables and on simple
ordinal logistic regression for ordinal variables, with 2-tailed P<0.05 considered as
statistically significant.
doi: 10.1371/journal.pone.0081120.t001
Table 2. Multivariable model of factors associated with
odds Adjusted odds ratios for covariates independently
associated with the risk of community-acquired pneumonia
in participants with 25-hydroxyvitamin D levels <30 ng/mL
versus ≥30 ng/mL.
 Odds Ratio (95% Confidence Interval)
25(OH)D (< 30 ng/ml vs. ≥30 ng/ml) 1.56 (1.17-2.07)
Age (Years) 1.10 (1.01-1.19)
Race (White vs. Non-white) 1.64 (1.21-2.21)
Asthma 2.70 (2.00-3.66)
Chronic obstructive pulmonary disease 4.11 (3.09-5.47)
Congestive heart failure 1.87 (1.22-2.88)
Diabetes mellitus 1.53 (1.08-2.18)
25(OH)D = 25-hydroxyvitamin D.
doi: 10.1371/journal.pone.0081120.t002
In addition to the persuasive cellular, molecular, and
biochemical data to support the relationship between 25(OH)D
levels and immune function, associations of vitamin D status
with the risk of various community-acquired and nosocomial
infections are also evident. Indeed, 25(OH)D levels appear to
influence the risk of URIs [28,29], bronchiolitis [30,31], and
chronic sinusitis [32,33] in community dwelling adults and
children. Moreover, emerging evidence suggests that vitamin D
status may be associated with the risk of surgical site infections
in post-operative patients [34] and with the risk of blood stream
infections in hospitalized patients [35]. Taken altogether, these
observations add to the growing body of evidence, which points
to the critical role that vitamin D status may play in influencing
host susceptibility to various infections. On the other hand,
randomized, placebo-controlled, clinical trials (RCTs) have
been less definitive [36,37]. While a handful of studies have
attempted to investigate the effect of vitamin D
supplementation on URIs [38-41], pneumonia [42,43], and
mycobacterial pulmonary infections [44-46], RCTs
demonstrating no effect have been criticized for the use of
small sample sizes [38,40,44], low doses of vitamin D
supplementation [38], intermittent dosing strategies that may
have allowed for significant variation in 25(OH)D levels
between doses [42,45], and for unexpectedly recruiting
participants with 25(OH)D levels near 30 ng/mL at baseline
[39].
Although the results of our present study are compelling, it is
important to discuss potential limitations. Observational studies
do not provide the highest level of clinical evidence, but they
can highlight the existence or absence of a true effect and
direct future research. Moreover, such cross-sectional studies
may be limited by potential for confounding and the lack of a
randomly distributed exposure. Despite adjustment for multiple
potential confounders, there may still be residual confounding,
which accounts for the observed differences in outcomes.
Specifically, low vitamin D status may simply be a reflection of
poor general health or suboptimal nutritional state, for which we
are unable to fully adjust. We are also unable to fully adjust for
lack of sun exposure (though we did control for the season
during which blood draws were performed), physical activity,
and immunization status. Although we are unable to directly
control for cases of hospital-acquired pneumonia, the risk of
including such individuals is small given that: 1) the NHANES
III cohort represents an ambulatory, non-institutionalized group
of participants; 2) we controlled for several major risk factors
associated with low vitamin D status and high risk of requiring
hospitalization; and 3) our regression analysis considered
several covariates known to be associated with the severity of
CAP. Given the confines of the NHANES III survey, a further
limitation is that we were unable to control for the exact amount
of time between the reported cases of CAP and the timing of
blood draws. As such, we cannot rule out the possibility of
reverse causation (i.e. low vitamin D status leads to CAP vs.
CAP results in low vitamin D status). However, in non-
hospitalized individuals, 25(OH)D levels tend to be relatively
consistent over time (intra-person Pearson correlation
coefficient of 0.70 at three years between blood draws
following adjustments for age, race, and season) [47].
Vitamin D and Community-Acquired Pneumonia
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Nonetheless, vitamin D status may be influenced by critical
illness [48], and therefore 25(OH)D levels may have been
different at the time that participants developed CAP. And
finally, the NHANES III dataset relies on a self reported history
of CAP, which may be prone to inaccurate reporting. These
and other potential issues will need to be addressed in future
studies in order to replicate and extend our findings.
While the results of the current study indicate, that on
aggregate, participants with 25(OH)D levels <30 ng/mL had a
significantly higher risk of CAP compared to the group of
participants with levels ≥30 ng/mL, we do note two peculiar
observations. First, when individuals at the lower end of the
25(OH)D spectrum are further subdivided and compared to
individuals with levels ≥30 ng/mL, as expected, those with
levels <10 ng/mL had the highest odds of CAP (OR 2.25).
However, the odds of CAP among participants with 25(OH)D
levels of 10-19.9 ng/mL (OR 1.26) appeared to be lower than in
those with levels of 20-29.9 ng/mL (OR 1.70) when both groups
were compared to participants with 25(OH)D levels ≥30 ng/mL.
While the incidence of CAP in participants with 25(OH)D levels
of 10-19.9 ng/mL was significantly lower than that in the other
two <30 ng/mL 25(OH)D subgroups (Table 1), a dose-response
association remains apparent on the cumulative frequency
LOWESS analysis (Figure 1). And second, while previous
studies have suggested that ethnic minorities in the United
States are at a greater risk for CAP than their white
counterparts [49,50], our results differ, despite an intentional
oversampling of non-whites in the NHANES III survey. Further
studies are needed to address these unexpected observations.
Conclusion
In summary, these data demonstrate that low 25(OH)D
levels are strongly associated with history of CAP in a large
nationally-representative cohort of non-institutionalized, adults
in the United States. Longitudinal studies are required to
confirm our findings and establish the mechanisms underlying
these observations. If confirmed, high-quality randomized,
controlled trials will be necessary to determine whether vitamin
D supplementation therapy among adults with low vitamin D
status may affect the incidence and severity of CAP in the
general population.
Figure 1.  Locally weighted scatterplot smoothing (LOWESS) analysis to show the relationship between increasing 25-
hydroxyvitamin D levels and the cumulative frequency of community-acquired pneumonia.  CAP = community acquired
pneumonia; 25(OH)D = 25-hydroxyvitamin D.
doi: 10.1371/journal.pone.0081120.g001
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